{
  "abstract": "Digestive neuroendocrine carcinoma (NEC) is a rare and highly aggressive malignancy, with an annual incidence of approximately 0.4–0.8 per 100,000 population. Due to its biological similarities with small cell lung cancer (SCLC), regimens such as etoposide plus cisplatin, irinotecan plus cisplatin, and etoposide plus carboplatin (EC) have been adopted as the standard treatments in unresectable or recurrent digestive NEC. However, its prognosis remains poor, thus requiring new treatment strategies. Immune checkpoint inhibitors plus cytotoxic chemotherapy have shown promise in the treatment of extensive-stage SCLC, warranting further exploration of their potential role in digestive NEC. An open-label randomized phase III investigator-initiated trial has been conducted since November 2023 to confirm the superiority of adding durvalumab to EC in chemotherapy-naive patients with unresectable or recurrent digestive NEC. A total of 74 patients will be enrolled from 14 institutions over 3 years. The primary endpoint is overall survival, while the secondary endpoints are progression-free survival, objective response rate, and incidence of adverse events.\n\nClinical trial registration: jRCT2031230456 (https://jrct.mhlw.go.jp/latest-detail/jRCT2031230456).",
  "abstract_shown": true,
  "affiliations": [
    "Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan",
    "Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan",
    "Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan",
    "Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan",
    "Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan",
    "Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan",
    "Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan",
    "Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan",
    "Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan",
    "Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan",
    "Department of Cancer Center, Hokkaido University Hospital, Sapporo, Japan",
    "Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan",
    "Third Department of Internal Medicine, University of Toyama, Toyama, Japan",
    "Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya, Japan",
    "Department of Gastroenterology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan",
    "Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"
  ],
  "article_type": "methods article",
  "arxiv": null,
  "author_total": 21,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yusuke Sano"
    },
    {
      "affs": [
        1
      ],
      "name": "Yuta Maruki"
    },
    {
      "affs": [
        1
      ],
      "name": "Chigusa Morizane"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Shogo Nomura"
    },
    {
      "affs": [
        0
      ],
      "name": "Haruhiko Fukuda"
    },
    {
      "affs": [
        3
      ],
      "name": "Masafumi Ikeda"
    },
    {
      "affs": [
        4
      ],
      "name": "Masato Ozaka"
    },
    {
      "affs": [
        5
      ],
      "name": "Satoshi Kobayashi"
    },
    {
      "affs": [
        6
      ],
      "name": "Kazuyoshi Ohkawa"
    },
    {
      "affs": [
        7
      ],
      "name": "Nobumasa Mizuno"
    },
    {
      "affs": [
        8
      ],
      "name": "Hidetaka Tsumura"
    },
    {
      "affs": [
        9
      ],
      "name": "Nao Fujimori"
    },
    {
      "affs": [
        10
      ],
      "name": "Yoshito Komatsu"
    },
    {
      "affs": [
        11
      ],
      "name": "Noboru Takata"
    },
    {
      "affs": [
        12
      ],
      "name": "Ichiro Yasuda"
    },
    {
      "affs": [
        13
      ],
      "name": "Kohei Nakachi"
    },
    {
      "affs": [
        14
      ],
      "name": "Toru Otsuru"
    },
    {
      "affs": [
        15
      ],
      "name": "Takuya Honda"
    },
    {
      "affs": [
        1
      ],
      "name": "Takuji Okusaka"
    },
    {
      "affs": [
        5
      ],
      "name": "Makoto Ueno"
    },
    {
      "name": "on behalf of the Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/612d7dm7ycnr6.bib",
  "cited_by": 0,
  "doi": "10.1080/14796694.2026.2749305",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13757589/",
  "id": "612d7dm7ycnr6",
  "issns": [
    "1479-6694",
    "1744-8301"
  ],
  "landing_url": "https://doi.org/10.1080/14796694.2026.2749305",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Clinical Trial Protocol"
    ],
    [
      "heading",
      "Method"
    ],
    [
      "openalex",
      "2730|Neuroendocrine Tumor Research Advances"
    ]
  ],
  "openalex": "W7223215749",
  "pdf_url": "https://www.tandfonline.com/doi/pdf/10.1080/14796694.2026.2749305?needAccess=true",
  "pmcid": "PMC13757589",
  "pmid": "42911120",
  "published": "2026-10-22",
  "publisher": "Taylor & Francis",
  "ris": "https://research.draconitic.com/paper/612d7dm7ycnr6.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:23:11Z",
      "native_id": "PMC13757589",
      "source": "pmc",
      "url": "https://doi.org/10.1080/14796694.2026.2749305"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Neuroendocrine Tumor Research Advances",
      "subfield": "oncology"
    }
  ],
  "title": "Durvalumab plus etoposide–carboplatin for advanced digestive neuroendocrine carcinoma: a phase III trial (JCOG2107E)",
  "title_text": "Durvalumab plus etoposide–carboplatin for advanced digestive neuroendocrine carcinoma: a phase III trial (JCOG2107E)",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:23:11Z",
  "url": "https://research.draconitic.com/paper/612d7dm7ycnr6",
  "venue": "Future Oncology",
  "versions": []
}